Nov 3 (Reuters) - OSE IMMUNOTHERAPEUTICS SA OSE.PA :
- SERVIER AND OSE IMMUNOTHERAPEUTICS ANNOUNCE COMPLETION OF PATIENT ENROLLMENT IN THE PHASE 2A CLINICAL TRIAL OF OSE-127/S95011 IN PRIMARY SJÖGREN'S SYNDROME
- STUDY INCLUDES 48 PATIENTS ACROSS A SCORE OF CENTERS LOCATED IN UNITED STATES, AUSTRALIA AND EUROPE
- RESULTS ARE EXPECTED IN 2023
